Form 8-K - Current report:
SEC Accession No. 0001193125-21-301165
Filing Date
2021-10-18
Accepted
2021-10-18 17:06:44
Documents
14
Period of Report
2021-10-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d119768d8k.htm   iXBRL 8-K 29586
2 EX-99.1 d119768dex991.htm EX-99.1 9891
6 GRAPHIC g119768g1018225857160.jpg GRAPHIC 6171
  Complete submission text file 0001193125-21-301165.txt   175893

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA wve-20211015.xsd EX-101.SCH 2914
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE wve-20211015_lab.xml EX-101.LAB 18072
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE wve-20211015_pre.xml EX-101.PRE 11400
7 EXTRACTED XBRL INSTANCE DOCUMENT d119768d8k_htm.xml XML 3332
Mailing Address 733 CONCORD AVENUE CAMBRIDGE MA 02138
Business Address 7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE U0 018936 617-949-2900
Wave Life Sciences Ltd. (Filer) CIK: 0001631574 (see all company filings)

EIN.: 000000000 | State of Incorp.: U0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37627 | Film No.: 211328832
SIC: 2834 Pharmaceutical Preparations